Somewhat Positive Media Coverage Somewhat Unlikely to Affect Evolent Health (EVH) Share Price
Media headlines about Evolent Health (NYSE:EVH) have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Evolent Health earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the technology company an impact score of 46.690079169587 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- Wall Street analysts’ favorites fizzled in 2017 (triblive.com)
- Brokers Offer Predictions for Evolent Health Inc’s FY2017 Earnings (EVH) (americanbankingnews.com)
- Evolent Health Inc Forecasted to Post Q3 2018 Earnings of ($0.01) Per Share (EVH) (americanbankingnews.com)
- Evolent Health Sees Unusually Large Options Volume (EVH) (americanbankingnews.com)
- Complete Genomics (GNOM) & Evolent Health (EVH) Financial Comparison (americanbankingnews.com)
EVH has been the subject of a number of research reports. SunTrust Banks reiterated a “buy” rating and issued a $30.00 price objective on shares of Evolent Health in a report on Wednesday, September 20th. Canaccord Genuity reiterated a “buy” rating and issued a $32.00 price objective on shares of Evolent Health in a report on Friday, October 6th. Cantor Fitzgerald reiterated a “buy” rating and issued a $30.00 price objective on shares of Evolent Health in a report on Sunday, December 3rd. Leerink Swann set a $25.00 price objective on Evolent Health and gave the stock a “buy” rating in a report on Saturday, November 18th. Finally, Goldman Sachs Group downgraded Evolent Health from a “conviction-buy” rating to a “buy” rating in a report on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and fourteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $28.00.
Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, November 2nd. The technology company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.04. Evolent Health had a negative return on equity of 5.05% and a negative net margin of 15.86%. The firm had revenue of $107.90 million during the quarter, compared to the consensus estimate of $104.49 million. During the same period last year, the company earned ($0.26) earnings per share. The company’s revenue was up 79.2% on a year-over-year basis. sell-side analysts anticipate that Evolent Health will post -0.55 EPS for the current fiscal year.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.